The UroLift® System

The UroLift® System is a straightforward minimally invasive treatment:

  • Rapid symptom relief
    and recovery1,2

  • Lowest catheter rate of the
    leading BPH procedures1,3-7

  • No new onset, sustained
    erectile or ejaculatory
    dysfunction2

  • Proven durability through
    five years3

A breakdown* of the various treatment options that patients usually opt for:

  • Medical Therapy
    (60-70%)

  • Watchful Waiting
    (30-35%)

  • Surgery
    (1-5%)

More than half of all men surveyed** who are currently prescribed medications experience unpleasant side effects. Dizziness, fatigue, and weakness/lack of energy are most common side effects. Each year, about 26% of BPH drug patients discontinue taking medication and are managed with watchful waiting*.

The UroLift® System is a proven option for patients seeking an alternative to
BPH medications or major surgery.

Find out how UroLift® compares to other treatments

Hear From Other Urologists***

  • Dr. Lincoln Tan

    MBBS (Singapore), MRCSEd, MMed (Surgery), FRCS (Urology)(RCPSG), FAMS (Urology)

    The UroLift® system has given me the opportunity to treat men with BPH who are seeking to preserve their sexual function.*3 These men previously would potentially be using medical therapy,...See more

    The UroLift® system has given me the opportunity to treat men with BPH who are seeking to preserve their sexual function.*3 These men previously would potentially be using medical therapy, in many cases with its attendant side effects. I have found that the UroLift® system can provide quick relief of urinary symptoms with a low risk of permanent side effects with improvement as early as two weeks, and is a welcome addition to our surgical armamentarium for BPH.1-3

  • Dr. Ronny Tan

    MBBS (Singapore), MRCSEd, MMed (Surgery), FAMS (Urology)

    Ejaculatory dysfunction has always been an unspoken issue for the longest time for patients undergoing treatment for BPH, be it medical or surgical treatment. With the arrival of UroLift®, as...See more

    Ejaculatory dysfunction has always been an unspoken issue for the longest time for patients undergoing treatment for BPH, be it medical or surgical treatment. With the arrival of UroLift®, as an andrologist, whenever I see a sexually active man who is embarking on the treatment for BPH, my aim now is to improve his urinary flow with less risk of compromise to his sexual function, whenever possible.*3,5,8
    I strongly believe that adding UroLift® to the armamentarium of the treatment options for BPH, we can now treat with less risk to ejaculatory and erectile function,*3,5,8 help preserve bladder function in the long run,9 and can get more men off of medication,3 decreasing the possibility of non-compliance to BPH medications.10

5-Year Data

Rapid, durable, and reproducible outcomes from treatment with the UroLift® System:

IPSS Improvement

Improvement in LUTS, as seen through average reduction in IPSS (International Prostate Symptom Score), has been consistent across the various studies, showing rapid relief within two weeks and sustained effect through five years.1 IPSS improvement at one year is better than seen with medications.2,8

Quality-of-Life Improvement

Quality of life also improved significantly, with the IPSS QOL and BPH Impact Index maintaining 50% and 52% improvements, respectively
at five years, p <0.0001.3

Flow Rate Improvement

In addition to improving LUTS, the UroLift® System treatment has demonstrated significant average improvement in peak urinary flow rate (Qmax) of 3.5 mL/sec (44%) that was sustained to five years, p <0.0001.3

Low Retreatment Rate

The rate of surgical intervention for failure to cure with the UroLift® System remains low for a BPH procedure, with approximately 13.6% over five years or about 2-3% per year.3 Over the first postoperative year, no additional surgical intervention was required for bladder neck contracture, bleeding, or stress incontinence in the pivotal study on UroLift® System.2

1. Roehrborn, AUA 2017 L.I.F.T. study 5 year presentation; 2. Madersbacher, Eur Urol 2005; 47: 499-504; 3. Yasushi, J Endourol 2016 ; 4. 5-year TUMT data – Mynderse, J Uro 2011; 5. 5-year data for TUNA, Hill, J Urol, 2015
MAC01255-01 Rev C-p17

Publications

Clinical results from over 22 select sponsored publications and over 140 peer-reviewed publications demonstrate that treatment with the UroLift® System offers rapid and significant improvements in symptoms, urinary flow and quality of life sustained through five years.3

View Publications

*Management estimates based on OUS market model for APAC.
**Content based on survey of 1,000 US men and 1,000 US women conducted by Teleflex l NeoTract 2020. Sample size may vary depending on qualifying questions.
***As with any medical procedure, individual results may vary.

References

1.

Shore, Can J Urol 2014

2.

Roehrborn, J Urology 2013

3.

Roehrborn et al. Can J Urol 2017

4.

Bachmann, Eur Urol 2014 May

5.

McVary, J Urol 2016

6.

Mollengarden, Prostate Cancer Prostatic Dis 2018

7.

Gilling, J Urol 2017

8.

AUA Guidelines 2003, 2020

9.

Tubaro, Drugs Aging 2003

10.

NeoTract US Market Model estimates for 2020 based on IQVIA data, data on file

Healthcare Professional Confirmation

The information on the page you are about to enter is intended for Healthcare Professionals only.
By clicking the box below, you confirm that you are a Healthcare Professional.

Continue